Free Trial

MoonLake Immunotherapeutics (MLTX) 10K Form and Latest SEC Filings 2026

MoonLake Immunotherapeutics logo
$17.01 -0.55 (-3.13%)
Closing price 04:00 PM Eastern
Extended Trading
$17.20 +0.19 (+1.14%)
As of 05:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest MoonLake Immunotherapeutics SEC Filings & Recent Activity

MoonLake Immunotherapeutics (NASDAQ:MLTX) has submitted 186+ documents to the U.S. Securities and Exchange Commission (SEC) since 2020. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in MoonLake Immunotherapeutics's financial statements. The most recent filing was a Form ARS submitted on April 21, 2026.

Form 4
MoonLake Immunotherapeutics Reports Ownership Change on Apr. 16, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

10-K
MoonLake Immunotherapeutics Files Annual Report on Feb. 25, 2026

The 10-K contains MoonLake Immunotherapeutics's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

MoonLake Immunotherapeutics SEC Filing History

Browse MoonLake Immunotherapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/21/2026 3:30 PM
MoonLake Immunotherapeutics (1821586) Filer
Form DEF 14A
04/21/2026 3:31 PM
MoonLake Immunotherapeutics (1821586) Filer
Form DEFA14A
04/21/2026 3:31 PM
MoonLake Immunotherapeutics (1821586) Filer
Form ARS
04/16/2026 3:10 PM
Bodenstedt Matthias (1920545) Reporting
MoonLake Immunotherapeutics (1821586) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/14/2026 4:55 PM
MoonLake Immunotherapeutics (1821586) Issuer
Santos da Silva Jorge (1920509) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/10/2026 5:06 PM
Bodenstedt Matthias (1920545) Reporting
MoonLake Immunotherapeutics (1821586) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/10/2026 8:56 AM
MoonLake Immunotherapeutics (1821586) Subject
Santos da Silva Jorge (1920509) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/09/2026 3:01 PM
Bodenstedt Matthias (1920545) Reporting
MoonLake Immunotherapeutics (1821586) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/02/2026 3:44 PM
BIOTECHNOLOGY VALUE FUND L P (918923) Filed by
MoonLake Immunotherapeutics (1821586) Subject
Form SCHEDULE 13D/A
04/02/2026 3:48 PM
BIOTECHNOLOGY VALUE FUND II LP (1102444) Reporting
BIOTECHNOLOGY VALUE FUND L P (918923) Reporting
Biotechnology Value Trading Fund OS LP (1660683) Reporting
BVF GP HOLDINGS LLC (1803809) Reporting
BVF I GP LLC (1803805) Reporting
BVF II GP LLC (1803806) Reporting
BVF INC/IL (1056807) Reporting
BVF PARTNERS L P/IL (1055947) Reporting
BVF Partners OS Ltd. (1660684) Reporting
LAMPERT MARK N (1233840) Reporting
MoonLake Immunotherapeutics (1821586) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/31/2026 8:18 PM
BVF PARTNERS L P/IL (1055947) Reporting
MoonLake Immunotherapeutics (1821586) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/25/2026 5:12 AM
MoonLake Immunotherapeutics (1821586) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/23/2026 5:04 AM
MoonLake Immunotherapeutics (1821586) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/17/2026 2:01 PM
Cormorant Asset Management, LP (1583977) Filed by
MoonLake Immunotherapeutics (1821586) Subject
Form SCHEDULE 13G
01/08/2026 7:00 AM
MoonLake Immunotherapeutics (1821586) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/22/2025 3:01 PM
MoonLake Immunotherapeutics (1821586) Issuer
Santos da Silva Jorge (1920509) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/22/2025 3:02 PM
MoonLake Immunotherapeutics (1821586) Issuer
Reich Kristian (1920553) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/22/2025 3:02 PM
Bodenstedt Matthias (1920545) Reporting
MoonLake Immunotherapeutics (1821586) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/10/2025 3:29 PM
MoonLake Immunotherapeutics (1821586) Issuer
Reich Kristian (1920553) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/10/2025 3:29 PM
MoonLake Immunotherapeutics (1821586) Issuer
Santos da Silva Jorge (1920509) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/08/2025 9:36 AM
MoonLake Immunotherapeutics (1821586) Subject
Santos da Silva Jorge (1920509) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/08/2025 9:07 AM
MoonLake Immunotherapeutics (1821586) Subject
Reich Kristian (1920553) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/14/2025 8:03 AM
Avoro Capital Advisors LLC (1633313) Filed by
MoonLake Immunotherapeutics (1821586) Subject
Form SCHEDULE 13G/A
11/10/2025 4:27 PM
BIOTECHNOLOGY VALUE FUND L P (918923) Filed by
MoonLake Immunotherapeutics (1821586) Subject
Form SCHEDULE 13D/A
11/05/2025 4:26 PM
MoonLake Immunotherapeutics (1821586) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/05/2025 4:25 PM
MoonLake Immunotherapeutics (1821586) Filer
Form 424B5
11/05/2025 10:40 AM
FMR LLC (315066) Filed by
MoonLake Immunotherapeutics (1821586) Subject
Form SCHEDULE 13G/A
11/05/2025 6:00 AM
MoonLake Immunotherapeutics (1821586) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/05/2025 6:02 AM
MoonLake Immunotherapeutics (1821586) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/09/2025 8:01 AM
Bodenstedt Matthias (1920545) Reporting
MoonLake Immunotherapeutics (1821586) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/01/2025 4:22 PM
Chen Bihua (1599214) Reporting
Cormorant Asset Management, LP (1583977) Reporting
Cormorant Global Healthcare Master Fund, LP (1618442) Reporting
Cormorant Private Healthcare Fund II, LP (1747677) Reporting
Cormorant Private Healthcare Fund III LP (1817320) Reporting
Cormorant Private Healthcare Fund IV LP (1871297) Reporting
MoonLake Immunotherapeutics (1821586) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/01/2025 4:23 PM
Chen Bihua (1599214) Filed by
MoonLake Immunotherapeutics (1821586) Subject
Form SCHEDULE 13G/A
09/29/2025 6:15 AM
MoonLake Immunotherapeutics (1821586) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/04/2025 3:01 PM
MoonLake Immunotherapeutics (1821586) Issuer
Reich Kristian (1920553) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/14/2025 5:57 AM
Avoro Capital Advisors LLC (1633313) Filed by
MoonLake Immunotherapeutics (1821586) Subject
Form SCHEDULE 13G
08/05/2025 6:01 AM
MoonLake Immunotherapeutics (1821586) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/05/2025 6:04 AM
MoonLake Immunotherapeutics (1821586) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/03/2025 12:23 PM
MoonLake Immunotherapeutics (1821586) Subject
Moukheibir Catherine (1772130) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/09/2025 6:16 PM
BIOTECHNOLOGY VALUE FUND II LP (1102444) Reporting
BIOTECHNOLOGY VALUE FUND L P (918923) Reporting
Biotechnology Value Trading Fund OS LP (1660683) Reporting
BVF GP HOLDINGS LLC (1803809) Reporting
BVF I GP LLC (1803805) Reporting
BVF II GP LLC (1803806) Reporting
BVF INC/IL (1056807) Reporting
BVF PARTNERS L P/IL (1055947) Reporting
BVF Partners OS Ltd. (1660684) Reporting
LAMPERT MARK N (1233840) Reporting
MoonLake Immunotherapeutics (1821586) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 8:05 AM
MoonLake Immunotherapeutics (1821586) Issuer
Phillips Andrew John (1921956) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 8:06 AM
MoonLake Immunotherapeutics (1821586) Issuer
Moukheibir Catherine (1772130) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 8:07 AM
MoonLake Immunotherapeutics (1821586) Issuer
Xavier Ramnik (1920780) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 8:07 AM
Loy Spike (1920549) Reporting
MoonLake Immunotherapeutics (1821586) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 8:08 AM
MoonLake Immunotherapeutics (1821586) Issuer
Sturge Simon (1920785) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025 3:30 PM
MoonLake Immunotherapeutics (1821586) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/14/2025 9:45 AM
MoonLake Immunotherapeutics (1821586) Subject
PRICE T ROWE ASSOCIATES INC /MD/ (80255) Filed by
Form SCHEDULE 13G/A
(Data available from 1/1/2016 forward)

MoonLake Immunotherapeutics SEC Filings - Frequently Asked Questions

MoonLake Immunotherapeutics (MLTX) has submitted 186+ filings to the SEC since 2020. You can browse the complete history or filter by form type using the tools above.

MoonLake Immunotherapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on MoonLake Immunotherapeutics's financial statements page.

The most recent filing was a Form ARS submitted on April 21, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:MLTX) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners